GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kineta Inc (OTCPK:KANT) » Definitions » ROA %

KANT (Kineta) ROA % : -543.63% (As of Jun. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Kineta ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Kineta's annualized Net Income for the quarter that ended in Jun. 2024 was $-10.42 Mil. Kineta's average Total Assets over the quarter that ended in Jun. 2024 was $1.92 Mil. Therefore, Kineta's annualized ROA % for the quarter that ended in Jun. 2024 was -543.63%.

The historical rank and industry rank for Kineta's ROA % or its related term are showing as below:

KANT' s ROA % Range Over the Past 10 Years
Min: -411.9   Med: -93.6   Max: -56.3
Current: -246.64

During the past 4 years, Kineta's highest ROA % was -56.30%. The lowest was -411.90%. And the median was -93.60%.

KANT's ROA % is ranked worse than
94.41% of 1503 companies
in the Biotechnology industry
Industry Median: -35.74 vs KANT: -246.64

Kineta ROA % Historical Data

The historical data trend for Kineta's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kineta ROA % Chart

Kineta Annual Data
Trend Dec20 Dec21 Dec22 Dec23
ROA %
-56.30 -85.46 -411.90 -101.74

Kineta Quarterly Data
Dec20 Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.11 -152.58 -101.17 -644.20 -543.63

Competitive Comparison of Kineta's ROA %

For the Biotechnology subindustry, Kineta's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kineta's ROA % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kineta's ROA % distribution charts can be found below:

* The bar in red indicates where Kineta's ROA % falls into.



Kineta ROA % Calculation

Kineta's annualized ROA % for the fiscal year that ended in Dec. 2023 is calculated as:

ROA %=Net Income (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=-14.099/( (17.435+10.281)/ 2 )
=-14.099/13.858
=-101.74 %

Kineta's annualized ROA % for the quarter that ended in Jun. 2024 is calculated as:

ROA %=Net Income (Q: Jun. 2024 )/( (Total Assets (Q: Mar. 2024 )+Total Assets (Q: Jun. 2024 ))/ count )
=-10.416/( (2.433+1.399)/ 2 )
=-10.416/1.916
=-543.63 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Jun. 2024) net income data. ROA % is displayed in the 30-year financial page.


Kineta  (OTCPK:KANT) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Jun. 2024 )
=Net Income/Total Assets
=-10.416/1.916
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-10.416 / 0)*(0 / 1.916)
=Net Margin %*Asset Turnover
=N/A %*0
=-543.63 %

Note: The Net Income data used here is four times the quarterly (Jun. 2024) net income data. The Revenue data used here is four times the quarterly (Jun. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Kineta ROA % Related Terms

Thank you for viewing the detailed overview of Kineta's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


Kineta Business Description

Traded in Other Exchanges
Address
7683 SE 27th Street, Suite 481, Mercer Island, WA, USA, 98040
Kineta Inc is a clinical-stage biotechnology company with a mission to develop next generation immunotherapies that transform patients' lives. The company's asset is KVA12.1, a VISTA blocking immunotherapy.
Executives
Raymond J. Bartoszek director C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Shawn Iadonato director, officer: Chief Executive Officer C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Craig W. Philips officer: President C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Pauline Kenny officer: General Counsel C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Keith Baker officer: Chief Financial Officer C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Thierry Guillaudeux officer: Chief Scientific Officer C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Scott J. Dylla director C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Marion R Foote director C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Michael D Wyzga officer: See Remarks C/O YUMANITY, INC., 40 GUEST STREET, SUITE 4410, BOSTON MA 02135
Devin Whittemore Smith officer: SVP and General Counsel C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 286, WALTHAM MA 02451
Kimberlee C Drapkin director PREDIX PHARMACEUTICALS HOLDINGS, INC., 4 MAGUIRE ROAD, LEXINGTON MA 02421
Ajay Verma officer: EVP, Head of R&D C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140
Lynne Zydowsky director C/O YUMANITY THERAPEUTICS, INC., 40 GUEST STREET, BOSTON MA 02135
Susan L. Lindquist Exempt Marital Trust 10 percent owner C/O NANCY E. DEMPZE, HEMENWAY & BARNES, LLP, 75 STATE STREET, BOSTON MA 02109
Susan L. Lindquist Massachusetts Non-exempt Marital Trust 10 percent owner C/O NANCY DEMPZE, HEMENWAY & BARNES, LLP, 75 STATE STREET, BOSTON MA 02109